Weijing Sun MD, FACP

Weijing Sun, MD is currently the Sprint Professor of Medical Oncology; Professor of Medical Oncology and Cancer Biology; the Director of the Medical Oncology Division at the University of Kansas School of Medicine; and the Associate Director of the University of Kansas Cancer Center.

He graduated from Shanghai Medical University (now merged with Fudan University). He had his Internal Medicine residency training at Loyola University Medical Center, and Hematology-Oncology fellowship training at the University of Pennsylvania. He served his assistant and associate professorship and had been the director of GI Medical Oncology at the University of Pennsylvania until 2012. He then served his professorship, as the director of GI Medical Oncology and co-director of GI Cancer Research Excellence at the University of Pittsburgh until August 2017 when he accepted the current position at the University of Kansas.

He is a national and international expert in gastrointestinal cancers. He is focusing on the treatment and clinical research of GI malignancies, mainly on the development of new drugs and biologic/targeted-oriented agents in treatment/therapy (including translational and immune research) of GI cancers with great experiences in the early phase clinical trial (phase I, II) designing, protocol development, and conduction, and many of these have been published. He has served as a member of the ECOG-ACRIN GI core committee; a member of NCI GI Cancer’s Steering Committee Hepatobiliary Task Force. He has served as PI for many investigate-initiated studies and pharmaceutical company trials.

He has authored many publications including original clinical research articles, reviews, and invited editorial comments in a variety of peer-reviewed journals. He has also written chapters as a GI oncology expert for several medical textbooks including WebMD, the Textbook of Gastroenterology. He is the editor-in-chief of the textbook of Multidisciplinary Therapy of GI Malignancies. He has had more than 130 publications. He is serving as a member of editorial boards or review committees for several professional journals. He serves as deputy editor-in-chief of the Journal of Hematology and; Oncology; and associated editor of the Journal of Practical Oncology.

He served ASCO (American Society of Clinical Oncology) scientific program committee (both colorectal and non-colorectal cancer subcommittees); and currently is serving as the head of the colorectal cancer education committee of the 2020 ASCO annual meeting. He serves as the activity director of ISGIO (International Society of Gastrointestinal Oncology) and was recently elected as the president-elect of the organization. He served as the president and the board chair of CAHON (Chinses American Hematologist-Oncologist Network).